WO2001037853A3 - Methods and agents for the inhibition of smooth muscle cell proliferation - Google Patents

Methods and agents for the inhibition of smooth muscle cell proliferation Download PDF

Info

Publication number
WO2001037853A3
WO2001037853A3 PCT/US2000/032005 US0032005W WO0137853A3 WO 2001037853 A3 WO2001037853 A3 WO 2001037853A3 US 0032005 W US0032005 W US 0032005W WO 0137853 A3 WO0137853 A3 WO 0137853A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibition
cell proliferation
smooth muscle
muscle cell
methods
Prior art date
Application number
PCT/US2000/032005
Other languages
French (fr)
Other versions
WO2001037853A2 (en
WO2001037853A9 (en
Inventor
Sivaram Pillarisetti
Original Assignee
Long Island Jewish Res Inst
Sivaram Pillarisetti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Long Island Jewish Res Inst, Sivaram Pillarisetti filed Critical Long Island Jewish Res Inst
Priority to AU20456/01A priority Critical patent/AU2045601A/en
Publication of WO2001037853A2 publication Critical patent/WO2001037853A2/en
Publication of WO2001037853A3 publication Critical patent/WO2001037853A3/en
Publication of WO2001037853A9 publication Critical patent/WO2001037853A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention is directed toward the inhibition of smooth muscle cell proliferation in the prophylaxis and treatment of vasculopathies such as atherosclerosis using perlecan, an active fragment of perlecan, or by gene therapy methods for introducing an expression vector comprising perlecan or an active fragment thereof.
PCT/US2000/032005 1999-11-23 2000-11-22 Methods and agents for the inhibition of smooth muscle cell proliferation WO2001037853A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU20456/01A AU2045601A (en) 1999-11-23 2000-11-22 Methods and agents for the inhibition of smooth muscle cell proliferation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16712699P 1999-11-23 1999-11-23
US60/167,126 1999-11-23
US71695600A 2000-11-21 2000-11-21
US09/716,956 2000-11-21

Publications (3)

Publication Number Publication Date
WO2001037853A2 WO2001037853A2 (en) 2001-05-31
WO2001037853A3 true WO2001037853A3 (en) 2001-11-01
WO2001037853A9 WO2001037853A9 (en) 2002-01-03

Family

ID=26862881

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/032005 WO2001037853A2 (en) 1999-11-23 2000-11-22 Methods and agents for the inhibition of smooth muscle cell proliferation

Country Status (1)

Country Link
WO (1) WO2001037853A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020182587A1 (en) * 2001-03-02 2002-12-05 Sivaram Pillarisetti Methods and compositions for the treatment and prevention of smooth muscle cell proliferation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341006A2 (en) * 1988-05-03 1989-11-08 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
WO1994004178A1 (en) * 1992-08-12 1994-03-03 Bio-Technology General Corp. Method of inhibiting cell proliferation using apolipoprotein e
WO1998011140A1 (en) * 1996-09-11 1998-03-19 Pharmacia & Upjohn Ab A process for purifying apolipoproteins and a composition for use in the process
WO1999006054A1 (en) * 1997-07-30 1999-02-11 Cardiac Crc Nominees Pty. Ltd. Wound and injury treatment compositions and the use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341006A2 (en) * 1988-05-03 1989-11-08 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
WO1994004178A1 (en) * 1992-08-12 1994-03-03 Bio-Technology General Corp. Method of inhibiting cell proliferation using apolipoprotein e
WO1998011140A1 (en) * 1996-09-11 1998-03-19 Pharmacia & Upjohn Ab A process for purifying apolipoproteins and a composition for use in the process
WO1999006054A1 (en) * 1997-07-30 1999-02-11 Cardiac Crc Nominees Pty. Ltd. Wound and injury treatment compositions and the use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PAKA LATHA ET AL: "Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells: An underlying mechanism for the modulation of smooth muscle cell growth?", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 51, 17 December 1999 (1999-12-17), pages 36403 - 36408, XP002169477, ISSN: 0021-9258 *
PAKA LATHA ET AL: "Perlecan, heparan sulfate proteoglycan, mediates the anti-proliferative effect of apolipoprotein E: An underlying mechanism for the modulation of smooth muscle cell growth?", CIRCULATION, vol. 110, no. 18 SUPPL., 2 November 1999 (1999-11-02), 72nd Scientific Sessions of the American Heart Association;Atlanta, Georgia, USA; November 7-10, 1999, pages I.548, XP001002744, ISSN: 0009-7322 *

Also Published As

Publication number Publication date
WO2001037853A2 (en) 2001-05-31
WO2001037853A9 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
NO20003233D0 (en) 4-hydroquinquinoline-3-carboxamides and hydrazines as antivirals
NO20013554L (en) Anticonvulsant derivatives that can be used in the treatment of cluster headaches
ZA200200085B (en) Methods of treating and/or suppressing weight gain.
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
WO2002103103A3 (en) Fluorine-containing compounds and polymers derived therefrom
WO2000071703A3 (en) Inhibition of histone deacetylase
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
WO2003099217A3 (en) Methods of treating bacterial infections and diseases associated therewith
AU4270099A (en) Novel method for preparing cyclosporin derivatives
AU2001292579A1 (en) Methods and compounds for treating proliferative diseases
AU3902299A (en) Methods of treating microbial infection and therapeutic formulations therefor
AU2002311777A1 (en) Method of treating arthritis using lentiviral vectors in gene therapy
WO2000021513A3 (en) Methods for treating multiple sclerosis
MXPA04004372A (en) Heterocyclic derivatives of glycinamide and their medical use.
WO2000032765A3 (en) Ribozyme therapy for the treatment and/or prevention of restenosis
AU2672099A (en) Compositions and methods for wound healing
AP2000001984A0 (en) Combination of protein farnesyltrandferase and HMG COA reductase inhibitors and their use to treat cancer.
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
ES2136581A1 (en) Use of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives for the treatment of restenosis
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
WO2001037853A3 (en) Methods and agents for the inhibition of smooth muscle cell proliferation
AU2001285156A1 (en) Combination therapy for the treatment of migraine
WO2003053365A3 (en) Syn3 compositions and methods
AU2576901A (en) Agents and methods for the treatment of proliferative diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/7-7/7; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP